Today: 15 May 2026
LightPath Technologies Stock Just Hit a 52-Week High. Here’s Why LPTH Is Back in Focus
25 April 2026
2 mins read

LightPath Technologies Stock Just Hit a 52-Week High. Here’s Why LPTH Is Back in Focus

ORLANDO, Florida, April 24, 2026, 18:03 ET

  • Shares of LightPath Technologies jumped 10.05% to finish at $16.09, after touching $16.53 earlier Friday.
  • LPTH now trades above a handful of analyst targets set in recent months, upping the pressure on management to deliver.
  • Defense optics orders and infrared camera systems have been in focus for investors, with the company reporting a backlog that hit $97.8 million last quarter.

LightPath Technologies Inc. surged Friday, ending the session up 10.05% at $16.09 after hitting $16.53—marking a fresh 52-week high. Volume spiked to nearly 6.35 million shares, a sharp rise from Thursday’s 1.52 million, according to market data.

The rally’s significance? Investors are rethinking the small Orlando optics company’s pivot—from selling components to pushing upmarket with infrared camera systems, especially targeting defense and security. IR, or infrared, picks up heat signatures instead of visible light.

The stock zipped past several analyst targets. According to Benzinga, three analysts had pegged a consensus price of $13.33, with H.C. Wainwright offering the highest estimate at $15. By the end of Friday, LPTH shares were trading above both figures.

Scott Buck at H.C. Wainwright bumped up his price target on the stock to $15 from $10 back in February, maintaining a Buy call. He cited “elevated levels of demand,” mostly from the defense and security sectors. Buck highlighted an order for $9.6 million in cooled infrared cameras, along with LightPath’s $97.8 million backlog—both lending visibility to revenue for the remainder of fiscal 2026 and into fiscal 2027. StreetInsider.com

LightPath posted revenue of $16.4 million for its fiscal 2026 second quarter, jumping 120% from the same period last year. Gross profit landed at $6.0 million, a 212% surge. Adjusted EBITDA turned positive, hitting $0.6 million after recording a loss a year ago.

The messaging from the company has been clear. In February, Chief Executive Sam Rubin pointed to “accelerating revenue growth on strong orders,” crediting sales from G5 Infrared’s cameras and modules. PR Newswire

LightPath wants to shake its image as just a component supplier. The annual report outlines plans to pivot toward imaging subsystems and full systems, with BlackDiamond chalcogenide glass at the center. The material—used in infrared optics and positioned as a germanium alternative—is the company’s bet for this shift.

The company’s play here has a defense component. LightPath points to its cooled camera tech for long-range, border security, and anti-drone operations. They also argue the BlackDiamond materials help sidestep germanium bottlenecks.

Management’s been fleshing out its sales team lately. LightPath tapped Doug Schoen for senior VP of global sales and brought on Ryan Workman as VP of business development and product management on April 8. CEO Rubin said these additions are meant to help turn a “strong backlog into sustained revenue growth.” PR Newswire

LightPath isn’t alone in the space. Its annual report lays out competition on multiple fronts: raw materials, lenses, assemblies, and cameras. The company lists Teledyne FLIR as one of its rivals for standard products. Defense giants like Lockheed Martin and RTX show up on both sides of the ledger—they can be customers, but they’re also competitors.

The stock’s recent jump doesn’t leave much margin for setbacks. LightPath posted a second-quarter net loss of $9.4 million, deeper than the $2.6 million loss a year ago—acquisition-linked fair-value adjustments played a role. The company’s filings flag risks: rivals, pricing squeezes, customer sign-off delays, or softer demand could all weigh on results.

Right now, investors are chasing the defense-optics narrative, shelling out even before the company can prove steady profits. The real question: will that backlog actually convert to revenue as quickly as the market’s betting it will?

Stock Market Today

  • Key Advice for Investors: Focus on Long-Term Market Investment, Not Short-Term Fluctuations
    May 15, 2026, 6:19 AM EDT. The stock market has confounded many investors with strong returns despite economic challenges, including inflation and geopolitical tensions. The S&P 500 gained about 33% in the past year, the Dow rose roughly 23%, and the Nasdaq surged 47%. Experts caution against trying to predict short-term movements, which are highly volatile and influenced by unpredictable factors like trade tensions and supply disruptions. Historically, holding an investment such as an S&P 500 fund for longer periods significantly reduces the risk of losses. Short-term trading can result in locked-in losses and missed recovery gains, as illustrated by hypothetical scenarios involving the Vanguard S&P 500 ETF (VOO). Data shows one-year periods see negative returns 33% of the time, but this risk declines sharply over five- and ten-year horizons. Investors are advised to prioritize time in the market over timing it to enhance potential returns.

Latest articles

Mobix Labs Stock Soars 79% After Rare-Earth Deal Plan — Why MOBX Is Suddenly in the China Supply-Chain Fight

Mobix Labs Stock Soars 79% After Rare-Earth Deal Plan — Why MOBX Is Suddenly in the China Supply-Chain Fight

15 May 2026
Mobix Labs shares jumped 78.74% to $3.11 Thursday after it signed a non-binding letter of intent to acquire Special Project Delivery, a U.S. critical-minerals and energy-storage platform. The company also amended a convertible note with Leviston Resources, raising principal to $4 million for $833,000 in new cash. SPD was formed in 2019 and is based in Newport Beach, California.
HCW Biologics Stock News: Profit, Pipeline and Nasdaq Risk Put HCWB Back in Focus

HCW Biologics Stock News: Profit, Pipeline and Nasdaq Risk Put HCWB Back in Focus

15 May 2026
HCW Biologics posted first-quarter net income of $3.47 million on $6.54 million in revenue, reversing a year-earlier loss, after a licensing deal with Beijing-based Trimmune Biotech. The company remains below Nasdaq’s $1 minimum bid and awaits early human data from its lead autoimmune drug, HCW9302, in alopecia areata. HCW also reported positive animal study results for a lung drug targeting premature infants.
MicroAlgo Stock Jumps Before The Bell As Quantum Circuit Algorithm Puts MLGO Back In Play

MicroAlgo Stock Jumps Before The Bell As Quantum Circuit Algorithm Puts MLGO Back In Play

15 May 2026
MicroAlgo Inc. announced a new algorithm for automating quantum circuit design, sending its shares up 13.18% to $4.55 at Thursday’s close and 20.88% higher in pre-market trading Friday. The company said its tool can generate and evaluate quantum circuits without pre-set specs and tested it on standard problems, but did not disclose customers, pricing, or a launch date.
Datavault AI Stock Rises Before Q1 Results as Crypto Bill Vote Puts DVLT Back in Focus

Datavault AI Stock Rises Before Q1 Results as Crypto Bill Vote Puts DVLT Back in Focus

15 May 2026
Datavault AI shares climbed about 10% in early premarket trading ahead of its first-quarter results and webcast. The move follows a Senate committee vote advancing a crypto-market bill tied to Datavault’s tokenization strategy. The company recently raised $60 million in a stock sale to fund its GPU edge-network plan, raising dilution concerns. Shares were quoted at $0.5861, up from $0.55 in the recent offering.
Wolfspeed Stock Jumps 13% Before May 5 Earnings Test
Previous Story

Wolfspeed Stock Jumps 13% Before May 5 Earnings Test

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz
Next Story

US Stock Market Today: Live Updates 25.04.2026

Go toTop